Smart dosing of immunotherapy combo shows promise for kidney cancer
NCT ID NCT06860386
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 32 times
Summary
This phase II trial tests whether adjusting doses of two drugs—pembrolizumab (Keytruda) and axitinib (Inlyta)—based on tumor response can better control advanced kidney cancer. The study aims to enroll 75 adults with clear cell renal cell carcinoma that has spread. The trial is currently suspended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and axitinib (Inlyta)
What this could lead to
If successful, this could show that adjusting drug doses based on tumor response helps control advanced kidney cancer longer with fewer side effects.
What could go wrong
This is a small, early-phase trial that is currently suspended. The adaptive dosing approach may not improve outcomes, and side effects from the drugs can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.